A Phase 1 interventional study of tasimelteon in Circadian Rhythm Sleep Disorders, Non-24 Hour Sleep-Wake Disorder and Autism Spectrum Disorder, sponsored by Vanda Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-03-21.
Sponsored by Vanda Pharmaceuticals · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States — 10 open to participants now, 10 under way, 1 of them phase 3. Sleep Disorders, Circadian Rhythm · United States.
Among the 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States, this one is the 40th largest by enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2016, is one of 6 in phase 1, and was the 33rd registered.
135 studies on the registry are indexed under Sleep Disorders, Circadian Rhythm; 25 are open to participants now.
Browse Sleep Disorders, Circadian Rhythm studies →10 of the 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States are open now. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 16+
Leslie Swanson · Sites in United States
Ages 18–60
Axsome Therapeutics, Inc. · Sites in United States, Canada
Ages 18–65
Yale University · Sites in United States
Ages 18+
University of Colorado, Boulder · Sites in United States
Ages 16–40 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Sleep Disorders, Circadian Rhythm studies recruiting now, 7 (50%) set no upper age limit and 4 (29%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 3 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 59 across 102 interventional studies indexed under Sleep Disorders, Circadian Rhythm.
Median enrollment 50 across the 54 interventional studies, 55 across the 15 observational. Of the 57 that completed or were terminated, 20 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 69 have an industry lead sponsor. The 10 most frequent:
Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.
Vanda Pharmaceuticals has 9 studies filed under Sleep Disorders, Circadian Rhythm — fewer than ten, so there is no comparison to draw.
5 of the studies in Sleep Disorders, Circadian Rhythm with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06568367Phase 3Axsome Therapeutics, Inc.Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) | 2026-12 |
| NCT06226025Leslie SwansonCorrecting Circadian Rhythms to Breakthrough in Bipolar Disorder | 2026-12 |
| NCT06336525Brigham and Women's HospitalAdult Sleep Health in the Rural Appalachia and Mississippi Delta Region and Its Relationships With Cardiometabolic Health Disparities. | 2027-01-31 |
| NCT05463861Stanford UniversityLemborexant in Delayed Sleep Phase Syndrome | 2027-05-31 |
| NCT06809335Henry Ford Health SystemA Pilot of a Personalized Circadian mHealth to Improve Sleep in Night Shift Workers | 2027-06 |
Add all 5 to your calendar (.ics) → With an account.
Among the 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Open-label Study to Investigate the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents.
This study is an open-label, single dose, non-controlled study to evaluate the PK and safety of tasimelteon in children and adolescents from 3 years to less than 18 years of age who were legally blind and met the diagnostic criteria for CRSWD Non-24 per DSM-V or who were diagnosed with a Neurodevelopmental Disorder (like ASD and SMS) and had a nighttime sleep complaint.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
3 Diagnosis of SMS determined by a prior positive genetic test result as indicated by parent/guardian; Diagnosis of ASD as indicated by parent/guardian; or a diagnosis of Non-24 as determined by diagnostic criteria for the Circadian rhythm sleep-wake disorder, Non-24-hour sleep-wake hour type:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single-dose pharmacokinetics of tasimelteon
Drug: tasimelteon
Melatonin receptor agonist
Also known as: Hetlioz
Area under the curver (AUC) of tasimelteon and its metabolites
Time frame: Pre-dose, 15 minutes post dose, 30 minutes post dose,1 hour post dose, 2 hours post dose, 4 hours post dose
Maximum concetration (Cmax) of tasimelteon and its metabolites
Time frame: Pre-dose, 15 minutes post dose, 30 minutes post dose,1 hour post dose, 2 hours post dose, 4 hours post dose
Steady-state concentration (Css) of tasimelteon and its metabolites
Time frame: Pre-dose, 15 minutes post dose, 30 minutes post dose,1 hour post dose, 2 hours post dose, 4 hours post dose
Half-life of tasimelteon and its metabolites
Time frame: Pre-dose, 15 minutes post dose, 30 minutes post dose,1 hour post dose, 2 hours post dose, 4 hours post dose
Trough concentration (Ctrough) of tasimelteon and its metabolites
Time frame: Pre-dose, 15 minutes post dose, 30 minutes post dose,1 hour post dose, 2 hours post dose, 4 hours post dose
Safety and tolerability of tasimelteon as measured by spontaneous reporting of adverse events (AEs)
Time frame: Day 1
Safety and tolerability of tasimelteon as measured by Pediatric Adverse Event Reporting System (PAERS)
Time frame: Day 1
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2016 to primary completion in Dec 2017, 14 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tasimelteon
Sleep Disorders, Circadian Rhythm →